01 What is TB-500?
In plain English.
TB-500 is a lab-made peptide marketed as a recovery aid. Its name is a marketing label, not a scientific one: it refers to a shortened, synthetic sequence inspired by thymosin beta-4 (TB-4), a 43-amino-acid protein the body produces naturally, particularly at sites of injury. The vials sold to bodybuilders and gym-goers are not the same molecule as the full TB-4 used in clinical research, although vendors often blur the two.
This distinction matters: when you read about TB-4 healing corneas or repairing heart tissue in animal studies, that work was done with the full 43-residue protein (or its drug form, RGN-259), not the fragment sold online as "TB-500". Treat the two as related-but-different, and assume any TB-4 evidence transfers to TB-500 only loosely.
02 How it works
The simple version, then the science.
In animals, thymosin beta-4 appears to help injured tissue rebuild itself: it promotes new blood-vessel formation (angiogenesis), recruits cells that migrate into wounds, and dampens inflammation. The marketed TB-500 fragment is claimed to recapitulate these actions, on the basis that it includes the short "actin-binding" region thought to do much of the work.
Go deeper · the proposed mechanism
TB-4 is the most abundant member of the beta-thymosin family and binds G-actin, sequestering monomers and regulating cytoskeletal dynamics during cell migration. In rodent models it has been reported to upregulate VEGF and integrin-linked kinase (ILK) signalling, stimulate endothelial cell migration, and modulate inflammatory cytokines. These mechanisms are described for the full protein; whether the truncated TB-500 fragment produces the same downstream effects in humans is not established.
03 What it's used for
Each use graded by how strong the evidence actually is.
- PreclinicalSoft-tissue & wound healingRepeated rodent studies on dermal, corneal and cardiac wounds, using full TB-4, not the marketed fragment. No controlled human trials of TB-500 itself.
- PreclinicalCardiac repair after injuryA 2004 Nature paper showed TB-4 protected mouse heart cells after infarct. Promising preclinical signal; not yet translated to humans.
- AnecdotalTendon, ligament & muscle recovery in athletesPopular in performance circles, often stacked with BPC-157. Supported only by self-reports.
- AnecdotalHair regrowthFrequently claimed online. No controlled human data.
04 What the evidence says
Most of the science people cite under "TB-500" is actually evidence for the full thymosin beta-4 protein, and even that is overwhelmingly preclinical. RegeneRx's drug candidate RGN-259, an ophthalmic formulation of full TB-4, has progressed through Phase 2/3 trials for dry eye and corneal injury, with mixed results across primary endpoints. There are essentially no controlled human trials of the shortened "TB-500" fragment that's sold online. Animal results for wound healing and cardiac repair are real and reproducible in the literature, but the gap between a mouse and a human is wide, and the gap between full TB-4 and a marketing-named fragment widens it further. In short: an interesting preclinical signal for TB-4, very weak read-across to TB-500, and no proven human benefit.
05 Dosing & administration
Reported in the literature, information not advice.
Because there is no approved human protocol, no safe or effective dose has been established. Online communities describe milligram-range subcutaneous injections, often weekly, but these regimens are not backed by clinical evidence and the purity of research-grade vials is not regulated. A qualified clinician should be consulted before considering any peptide.
06 Side effects & safety
Long-term safety in humans is unknown, there are no large clinical trials of TB-500. Short-term reports from users include injection-site reactions and occasional lethargy. A specific theoretical concern is that TB-4 promotes angiogenesis (blood-vessel growth), which could in principle accelerate the growth of existing tumours; this has not been demonstrated clinically but is a reasonable reason for caution in anyone with cancer or a cancer history. Products sold as "TB-500" are unregulated research chemicals, contamination, mislabelling and dose-by-dose variation are real risks. People who are pregnant, breastfeeding, immunocompromised, or taking other medicines should be especially cautious.
07 Where to buy (research use only)
Vetted on quality and transparency, not an endorsement to use.
08 Legal & regulatory status
- UKNot licensed as a medicine. Sold only as a "research chemical", not for human use.
- USNot FDA-approved. Not on the FDA's list of bulk substances permitted for compounding.
- EU / AUS / CANNo approved human medicine containing TB-500. Sale for human use is unlawful in most jurisdictions; "research use only" framing is standard.
- Sport (WADA)Prohibited at all times under S2, Peptide Hormones, Growth Factors, Related Substances and Mimetics. Multiple racehorse positives have been reported under equine anti-doping rules.
09 Clinical studies & research
Primary sources. Read the science yourself.